





or a pharmaceutically acceptable salt thereof, wherein

R^a is C_{1-4} alkyl;

R^b is C_{1-4} alkyl; and

R^c is hydrogen or C_{1-4} alkyl.


In a further aspect of the present disclosure, there is provided a compound selected from the group consisting of:


,

,

,

,

, and

, or a pharmaceutically acceptable salt thereof.

In another aspect of the present disclosure, there is provided a pharmaceutical composition comprising a compound disclosed herein, or a pharmaceutically acceptable salt thereof; and a pharmaceutically acceptable carrier.

CLAIMS

1. A compound having the Formula **I**:



(**I**);

or a pharmaceutically acceptable salt thereof, wherein


R^a is $C_{2\text{-}4}$ alkyl or monocyclic $C_{3\text{-}6}$ cycloalkyl; and

R^b is $C_{1\text{-}4}$ alkyl.


2. The compound of claim 1, wherein R^a is ethyl, isopropyl, or cyclopropyl.

3. The compound of claim 1 or 2, wherein R^b is methyl or ethyl.


4. The compound of claim 1, wherein the compound is selected from the group consisting of:




,




,




,



,




, and



, or a pharmaceutically acceptable salt thereof.

5. A compound having the Formula **II**:


(**II**);

or a pharmaceutically acceptable salt thereof, wherein

R^a is C_{1-4} alkyl;

R^b is C_{1-4} alkyl; and

R^c is hydrogen or C_{1-4} alkyl.

6. The compound of claim 5, wherein R^a is methyl or ethyl.





7. The compound of claim 5 or 6, wherein R^b is methyl, ethyl, or isopropyl.

8. The compound of any one of claims 5-7, wherein R^c is hydrogen or methyl.







9. The compound of any one of claims 5-8, wherein R^c is hydrogen.

10. The compound of any one of claims 5-8, wherein R^c is methyl.

11. The compound of claim 5, wherein the compound is selected from the group consisting of:


,

,

, and

, or a pharmaceutically acceptable salt thereof.

12. A compound selected from the group consisting of:


,

,

,

,

, and

, or a pharmaceutically acceptable salt thereof.

13. A pharmaceutical composition comprising a compound of any one of claims 1-12, or a pharmaceutically acceptable salt thereof; and a pharmaceutically acceptable carrier.

14. Use of a compound of any one of claims 1-12, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition of claim 13, in the manufacture of a medicament for treating a condition relating to aberrant function of a sodium ion channel.

15. The use of claim 14, wherein the condition is a neurological or psychiatric disorder.

16. The use of claim 14 or 15, wherein the condition is epilepsy or an epilepsy syndrome.

17. The use of any one of claims 14-16, wherein the condition is selected from the group consisting of: a genetic epilepsy, a genetic epilepsy syndrome, a pediatric epilepsy, a pediatric epilepsy syndrome, and epileptic encephalopathy.

18. The use of claim 17, wherein the epileptic encephalopathy is selected from the group consisting of Dravet syndrome, infantile spasms, and Lennox-Gastaut syndrome.

19. The use of claim 14 or 15, wherein the condition is selected from the group consisting of epileptic encephalopathy, epileptic encephalopathy with SCN1A mutation, epileptic encephalopathy with SCN2A mutation, epileptic encephalopathy with SCN8A mutation,

early infantile epileptic encephalopathy, Dravet syndrome, Dravet syndrome with SCN1A mutation, generalized epilepsy with febrile seizures, intractable childhood epilepsy with generalized tonic-clonic seizures, infantile spasms, benign familial neonatal-infantile seizures, focal epilepsy with SCN3A mutation, cryptogenic pediatric partial epilepsy with SCN3A mutation, sudden unexpected death in epilepsy (SUDEP), Rasmussen encephalitis, malignant migrating partial seizures of infancy, autosomal dominant nocturnal frontal lobe epilepsy, KCNQ2 epileptic encephalopathy, and KCNT1 epileptic encephalopathy.

20. Use of the compound of any one of claims 1-12, or the pharmaceutically acceptable salt thereof, or a pharmaceutical composition of claim 13, in the manufacture of a medicament for treating a neurological disorder or a psychiatric disorder.

21. Use of a compound of any one of claims 1-12, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition of claim 13, in the manufacture of a medicament for treating a pain.

22. Use of a compound of any one of claims 1-12, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition of claim 13, in the manufacture of a medicament for treating or preventing a trigeminal autonomic cephalalgia (TAC) in a subject in need thereof, wherein the TAC is selected from the group consisting of paroxysmal hemicrania, hemicrania continua, short-lasting unilateral neuralgiform headache attacks with conjunctival injection and tearing (SUNCT), short-lasting unilateral neuralgiform headache attacks with cranial autonomic symptoms (SUNA), and long-lasting autonomic symptoms with hemicrania.

23. The use of claim 22, wherein the TAC is a short-lasting unilateral neuralgiform headache attack.

24. The use of claim 22 or 23, wherein the TAC is SUNCT or SUNA.

25. The use of any one of claims 22-24, wherein the subject has an inadequate response to at least one medication used for the treatment of a TAC.

26. Use of a compound of any one of claims 1-12, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition of claim 13, in the manufacture of a medicament for

treating or preventing a migraine in a subject in need thereof, wherein the migraine is selected from the group consisting of migraine without aura, migraine with aura, familial hemiplegic migraine type 1 (FHM1), familial hemiplegic migraine type 2 (FHM2), familial hemiplegic migraine type 4 (FHM4), and sporadic hemiplegic migraine (SHM).

27. The use of claim 26, wherein the migraine is selected from the group consisting of migraine without aura, migraine with aura, FHM1, FHM2, FHM4 and SHM.

28. The use of any one of claim 26 or 27, wherein the subject has an inadequate response to at least one medication used for the treatment of a migraine.

29. Use of a compound of any one of claims 1-12, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition of claim 13, in the manufacture of a medicament for treating or preventing cortical spreading depression (CSD).

30. Use of a compound of any one of claims 1-12, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition of claim 13, in the manufacture of a medicament for treating or preventing a cranial neuropathy or multiple cranial neuropathies, wherein the cranial neuropathy is selected from the group consisting of bell palsy, microvascular cranial nerve palsy, third nerve palsy, fourth nerve palsy, and sixth nerve palsy.

31. A compound of any one of claims 1-12, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition of claim 13, for use in therapy.